Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab
- 77 Downloads
To investigate morphological changes in myopic choroidal neovascularization (mCNV) using optical coherence tomography-angiography (OCT-A) after treatment with ranibizumab.
Retrospective analysis of consecutive patients over a 24-month period. All treatment-naïve mCNV were imaged at baseline with color pictures, spectral-domain OCT and OCT-A, and fluorescein angiography in selected cases. CNV morphology was classified at baseline and at 6 months. The CNV lesion surface was also compared.
Twenty-nine patients with a mean age of 70.3 ± 10.1 years were included. They received a mean number of 2.65 injections over 6 months. Best-corrected visual acuity improved from 62.2 to 68.5 letters (p = 0.004), with regression of exudation in 24 eyes (82.7%). Baseline CNV was classified into tree-in-bud (16 eyes), medusa (9 eyes), or sea-fan (4 eyes) pattern. At 6 months, no abnormal blood flow was observed in CNV in 13 eyes. Eyes with complete regression or evolution towards an indistinct pattern showed more often a complete regression of exudation than eyes with unchanged pattern (p = 0.007). The mean CNV surface significantly decreased from 0.19 to 0.08 mm2 (p < 0.0001).
An unchanged pattern was more often associated with exudation persistence, while a complete regression or evolution towards indistinct pattern was always associated with vascular inactivity. However, variable changes in mCNV were observed after anti-VEGF. Thus, OCT-A could be more useful in the diagnosis than in the follow-up of mCNV.
KeywordsMyopia Choroidal neovascularization Anti-VEGF Ranibizumab OCT-angiography
Compliance with ethical standards
Conflict of interest
Salomon Y. Cohen is a consultant for Allergan, Bayer, Novartis, Roche, Thea, and Tilak. Sandrine Tabary is a consultant for Bayer. Ala El Amen declares that he has no conflict of interest. Sarah Mrejen is a consultant for Allergan, Bayer, and Novartis. Gabriel Quentel is a consultant for Novartis. Audrey Giocanti-Auregan is a consultant for Allergan, Bayer, Novartis, and Optos Plc.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Agreement to perform the study was given by the Ethical Committee of the Federation France Macula.
- 15.El Ameen A, Cohen SY, Semoun O, Miere A, Srour M, Quaranta-El Maftouhi M, Oubraham H, Blanco-Garavito R, Querques G, Souied EH (2015) Type 2 neovascularization secondary to age related macular degeneration imaged by optical coherence tomography angiography. Retina 35:2212–2218CrossRefPubMedGoogle Scholar
- 18.Miere A, Butori P, Cohen SY, Semoun O, Capuano V, Jung C, Souied EH (2017) Vascular remodeling of choroidal neovascularization after anti-vascular endothelial growth factor therapy visualized on optical coherence tomography angiography. Retina Nov 23Google Scholar
- 21.Cheng Y, Li Y, Huang X, Qu Y.(2017) Application of optical coherence tomography angiography to assess anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization. Retina Dec 18. https://doi.org/10.1097/IAE.0000000000002005
- 22.Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M, RADIANCE Study Group (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682–692CrossRefPubMedGoogle Scholar
- 23.Ohno-Matsui K, Kawasaki R, Jonas JB, Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, Klaver CC, Moriyama M, Shinohara K, Kawasaki Y, Yamazaki M, Meuer S, Ishibashi T, Yasuda M, Yamashita H, Sugano A, Wang JJ, Mitchell P, Wong TY, META-analysis for Pathologic Myopia (META-PM) Study Group (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159:877–883CrossRefPubMedGoogle Scholar
- 31.Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, Miyake M, Yoshimura N (2013) Long-term effect of intravitreal injection of anti VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 251:1–7CrossRefPubMedGoogle Scholar
- 32.Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMedGoogle Scholar
- 36.Miyata M, Ooto S, Hata M, Yamashiro K, Tamura H, Akagi-Kurashige Y, Nakanishi H, Ueda-Arakawa N, Takahashi A, Kuroda Y, Wakazono T, Yoshikawa M, Yoshimura N (2016) Detection of myopic choroidal neovascularization using optical coherence tomography angiography. Am J Ophthalmol 165:108–114CrossRefPubMedGoogle Scholar
- 37.Ploner SB, Moult EM, Choi W, Waheed NK, Lee B, Novais EA, Cole ED, Potsaid B, Husvogt L, Schottenhamml J, Maier A, Rosenfeld PJ, Duker JS, Hornegger J, Fujimoto JG (2016) Toward quantitative optical coherence tomography angiography: visualizing blood flow speeds in ocular pathology using variable interscan time analysis. Retina 36(Suppl 1):S118–S126CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Jia Y, Bailey ST, Wilson DJ, Tan O, Klein ML, Flaxel CJ, Potsaid B, Liu JJ, Lu CD, Kraus MF, Fujimoto JG, Huang D (2014) Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 121:1435–1444CrossRefPubMedPubMedCentralGoogle Scholar